3 Blue-Chip Stocks Built for a Rotating Market Gilead Sciences (NASDAQ:GILD) Chief Commercial Officer and Head of Corporate ...
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. A move by the Trump administration ...
The state of Tennessee is cutting funding for HIV prevention, detection and treatment programs that are not affiliated with metro health departments as of May 31. Organizations across the state were ...
Gilead raised its previous guidance of $800 million in revenues from the long-acting PrEP injectable Yeztugo based on a ...
The U.S. Food and Drug Administration has approved Merck's once-daily, oral, combination regimen for HIV infections, the health regulator's website showed on Tuesday. The two-drug combination ...
Long-acting injectable antiretroviral therapy improves treatment outcomes in individuals with HIV type 1 (HIV 1) who face adherence challenges, thereby addressing a persistent barrier in routine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results